貝肯能源(002828.SZ):李青山完成減持25.48萬股 吳雲義擬繼續減持不超145.81萬股
格隆匯10月22日丨貝肯能源(002828.SZ)公佈,截至2021年10月22日,公司董事李青山、吳雲義披露的減持計劃期限已屆滿。其中,李青山於2021年5月25日-9月28日通過集中競價方式減持公司股份25.48萬股,佔公司總股本的0.1268%;而吳雲義未減持公司股份。
2021年10月22日,公司收到董事吳雲義的通知,吳雲義擬自該公吿披露之日起15個交易日後的6個月內,以集中競價、大宗交易方式合計減持公司股份不超過145.81萬股,即不超過公司總股本的0.72%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.